Literature DB >> 14744809

Histamine-induced inhibition of leukotriene biosynthesis in human neutrophils: involvement of the H2 receptor and cAMP.

Nicolas Flamand1, Hendrick Plante, Serge Picard, Michel Laviolette, Pierre Borgeat.   

Abstract

1. Histamine is generally regarded as a pro-inflammatory mediator in diseases such as allergy and asthma. A growing number of studies, however, suggest that this autacoid is also involved in the downregulation of human polymorphonuclear leukocyte (PMN) functions and inflammatory responses through activation of the Gs-coupled histamine H(2) receptor. 2. We report here that histamine inhibits thapsigargin- and ligand (PAF and fMLP)-induced leukotriene (LT) biosynthesis in human PMN in a dose-dependent manner. 3. The suppressive effect of histamine on LT biosynthesis was abrogated by the histamine H(2) receptor antagonists cimetidine, ranitidine, and tiotidine. In contrast, the histamine H(1), H(3), and H(4) receptor antagonists used in this study were ineffective in counteracting the inhibitory effect of histamine on the biosynthesis of LT in activated human PMN. 4. The inhibition of LT biosynthesis by histamine was characterized by decreased arachidonic acid release and 5-lipoxygenase translocation to the nuclear membrane. 5. Incubation of PMN with the cAMP-dependent protein kinase (PKA) inhibitor N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinoline-sulfonamide prevented the inhibitory effect of histamine on LT biosynthesis, suggesting an important role for PKA in this effect of histamine on LT biosynthesis in PMN. 6. These data provide the first evidences that, similarly to adenosine and prostaglandin E(2), histamine is a potent suppressor of LT biosynthesis, and support the concept that histamine may play a dual role in the regulation of inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14744809      PMCID: PMC1574237          DOI: 10.1038/sj.bjp.0705654

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

1.  Involvement of cytosolic phospholipase A2 and secretory phospholipase A2 in arachidonic acid release from human neutrophils.

Authors:  J Marshall; E Krump; T Lindsay; G Downey; D A Ford; P Zhu; P Walker; B Rubin
Journal:  J Immunol       Date:  2000-02-15       Impact factor: 5.422

2.  Differential regulation of phospholipase A2 (PLA2)-dependent Ca2+ signaling in smooth muscle by cAMP- and cGMP-dependent protein kinases. Inhibitory phosphorylation of PLA2 by cyclic nucleotide-dependent protein kinases.

Authors:  K S Murthy; G M Makhlouf
Journal:  J Biol Chem       Date:  1998-12-18       Impact factor: 5.157

3.  P-selectin mediates neutrophil adhesion to endothelial cell borders.

Authors:  A R Burns; R A Bowden; Y Abe; D C Walker; S I Simon; M L Entman; C W Smith
Journal:  J Leukoc Biol       Date:  1999-03       Impact factor: 4.962

Review 4.  Adenosine. An endogenous inhibitor of arachidonic acid release and leukotriene biosynthesis in human neutrophils.

Authors:  E Krump; P Borgeat
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

5.  Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2.

Authors:  J V Bonventre; Z Huang; M R Taheri; E O'Leary; E Li; M A Moskowitz; A Sapirstein
Journal:  Nature       Date:  1997-12-11       Impact factor: 49.962

6.  Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells.

Authors:  C Amsellem; W Czarlewski; M Lagarde; Y Pachéco
Journal:  Pulm Pharmacol Ther       Date:  1998       Impact factor: 3.410

7.  Role of 5-lipoxygenase products in the local accumulation of neutrophils in dermal inflammation in the rabbit.

Authors:  S Marleau; B Fruteau de Laclos; A B Sanchez; P E Poubelle; P Borgeat
Journal:  J Immunol       Date:  1999-09-15       Impact factor: 5.422

8.  Phosphodiesterase 4-dependent regulation of cyclic AMP levels and leukotriene B4 biosynthesis in human polymorphonuclear leukocytes.

Authors:  D Denis; D Riendeau
Journal:  Eur J Pharmacol       Date:  1999-02-19       Impact factor: 4.432

9.  Phosphorylation of cytosolic phospholipase A2 and the release of arachidonic acid in human neutrophils.

Authors:  S I Syrbu; W H Waterman; T F Molski; D Nagarkatti; J J Hajjar; R I Sha'afi
Journal:  J Immunol       Date:  1999-02-15       Impact factor: 5.422

10.  Suppression of leukotriene B4 biosynthesis by endogenous adenosine in ligand-activated human neutrophils.

Authors:  E Krump; S Picard; J Mancini; P Borgeat
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more
  14 in total

1.  Potentiation of NF-kappaB-dependent transcription and inflammatory mediator release by histamine in human airway epithelial cells.

Authors:  N S Holden; W Gong; E M King; M Kaur; M A Giembycz; R Newton
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

2.  Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006.

Authors:  Huafeng Shen; Suthat Liangpunsakul
Journal:  J Clin Gastroenterol       Date:  2016-08       Impact factor: 3.062

3.  The histamine H4 receptor is a potent inhibitor of adhesion-dependent degranulation in human neutrophils.

Authors:  Karim Dib; Tomas Perecko; Veronika Jenei; Cheryl McFarlane; David Comer; Vanessa Brown; Mwape Katebe; Torsten Scheithauer; Robin L Thurmond; Paul L Chazot; Madeleine Ennis
Journal:  J Leukoc Biol       Date:  2014-05-05       Impact factor: 4.962

Review 4.  New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents.

Authors:  Katerina Gurova
Journal:  Future Oncol       Date:  2009-12       Impact factor: 3.404

5.  Topical H2 antagonist prevents periodontitis in a rabbit model.

Authors:  H Hasturk; A Kantarci; N Ebrahimi; C Andry; M Holick; V L Jones; T E Van Dyke
Journal:  Infect Immun       Date:  2006-04       Impact factor: 3.441

6.  Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.

Authors:  Chenyu Sun; Yue Chen; Lei Hu; Yile Wu; Mingming Liang; Mubashir Ayaz Ahmed; Chandur Bhan; Zhichun Guo; Hongru Yang; Yijing Zuo; Yue Yan; Qin Zhou
Journal:  Dig Dis Sci       Date:  2021-02-24       Impact factor: 3.199

7.  Caffeic acid phenethyl ester and its amide analogue are potent inhibitors of leukotriene biosynthesis in human polymorphonuclear leukocytes.

Authors:  Luc H Boudreau; Jacques Maillet; Luc M LeBlanc; Jacques Jean-François; Mohamed Touaibia; Nicolas Flamand; Marc E Surette
Journal:  PLoS One       Date:  2012-02-09       Impact factor: 3.240

8.  COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.

Authors:  Robert W Malone; Philip Tisdall; Philip Fremont-Smith; Yongfeng Liu; Xi-Ping Huang; Kris M White; Lisa Miorin; Elena Moreno Del Olmo; Assaf Alon; Elise Delaforge; Christopher D Hennecker; Guanyu Wang; Joshua Pottel; Nora Smith; Julie M Hall; Gideon Shapiro; Anthony Mittermaier; Andrew C Kruse; Adolfo García-Sastre; Bryan L Roth; Jill Glasspool-Malone; Darrell O Ricke
Journal:  Res Sq       Date:  2020-06-22

9.  CD36 Shunts Eicosanoid Metabolism to Repress CD14 Licensed Interleukin-1β Release and Inflammation.

Authors:  Karina F Zoccal; Luiz G Gardinassi; Carlos A Sorgi; Alyne F G Meirelles; Karla C F Bordon; Isaias Glezer; Palmira Cupo; Alessandra K Matsuno; Valdes R Bollela; Eliane C Arantes; Francisco S Guimarães; Lúcia Helena Faccioli
Journal:  Front Immunol       Date:  2018-04-27       Impact factor: 7.561

10.  Impact of Famotidine Use on Clinical Outcomes of Hospitalized Patients With COVID-19.

Authors:  Jeffrey F Mather; Richard L Seip; Raymond G McKay
Journal:  Am J Gastroenterol       Date:  2020-10       Impact factor: 12.045

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.